Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Calon Earns Frost & Sullivan 2015 European Ventricular Assist Devices Technology Innovation Award Calon Cardio, the leader in next-generation devices for heart failure, is delighted to announce that it has been awarded the 2015 Frost & Sullivan European Ventricular Assist Devices Technology Innovation Award. The award, presented today at the Frost & Sullivan Awards event in Monte Carlo, recognises the innovative layout and promising blood trauma data arising from laboratory and pre-clinical studies. According to the Award adjudication report, the Calon Cardio MiniVADtm displays visionary innovation: “Calon Cardio has brought together expertise in mechanical engineering, electrical engineering, computational fluid dynamics and biomedical engineering to deliver its novel pump technology used in the development of MiniVAD. With the aim of developing a smaller and low-cost heart assist pump that will cause less blood damage, Calon Cardio has designed a fresh product whose design and process is not based on previously existing Ventricular Assist Devices. “The company’s strategy to separate the motor from the impeller in the MiniVAD has drastically brought down the power consumption of the device and has improved the hydraulic characteristics of the pump. By avoiding active magnetic levitation for the bearing system, Calon has been able to dramatically reduce the computational requirements and power consumption of the device. At 0.8 W/Litre/minute, the MiniVAD device is amongst the lowest in the industry and this level of performance will certainly make this product a benchmark for new VADs.” Commenting on the award, Calon CEO Simon Cartmell observed, “We are delighted that Frost & Sullivan has recognised the outstanding developments undertaken by the team at Calon. Our consistent mission is to launch a better VAD that enables clinicians to provide heart failure patients with improved options that cause lower blood damage-related adverse events and overall improved health economics. This award supports our belief that we are doing that better than other emerging competitors.” For more information, contact Simon Cartmell, Chief Executive Officer, on +44 (0)1792 602811.